F. Hoffmann-La Roche AG vs Target Corporation: Strategic Comparison

This in-depth comparison examines F. Hoffmann-La Roche AG and Target Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching F. Hoffmann-La Roche AG on its own, evaluating Target Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between F. Hoffmann-La Roche AG and Target Corporation is widest.

On the headline numbers, F. Hoffmann-La Roche AG reports annual revenue of $77.2B against $104.8B for Target Corporation, while their respective market capitalizations stand at $327.5B and $63.1B. F. Hoffmann-La Roche AG is headquartered in Switzerland and Target Corporation operates from United States, and those different home markets shape how each company competes.

F. Hoffmann-La Roche AG: Roche is not just a drug company with a diagnostics side business. Its strategic identity is an integrated healthcare model: test the patient, identify the biology, treat with a targeted therapy, and use outcome data to improve the next development cycle.

Target Corporation: Target is a retailer whose value comes from making mass retail feel curated. The business is strongest when stores, digital channels, owned brands and fulfillment services reinforce one another.

F. Hoffmann-La Roche AG and Target Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between F. Hoffmann-La Roche AG and Target Corporation.

F. Hoffmann-La Roche AG business model: Roche makes money from branded prescription medicines, biologics, oncology and specialty drugs, diagnostic instruments, diagnostic reagents, sequencing and molecular testing, diabetes care products, and clinical data assets. Pharmaceuticals drive the largest share of sales, while Diagnostics adds recurring reagent revenue and supports personalized healthcare.

Target Corporation business model: Target's model combines large-format stores, digital commerce, store-based fulfillment, owned brands, loyalty, same-day services and retail media. Stores are both shopping destinations and local fulfillment nodes.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of F. Hoffmann-La Roche AG stack up against those of Target Corporation.

F. Hoffmann-La Roche AG competitive advantage: Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health. Competitors can match pieces of this model, but few can connect medicines, tests, and real-world data at similar scale.

Target Corporation competitive advantage: Target's advantage is the mix of curated merchandise, owned brands, convenient stores, same-day fulfillment and a brand position between discount utility and design-led retail.

Future prospects matter as much as current results. The growth strategies below explain how F. Hoffmann-La Roche AG and Target Corporation each plan to expand from here.

F. Hoffmann-La Roche AG growth strategy: Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.

Target Corporation growth strategy: Target is focusing on merchandising authority, guest experience, technology acceleration, team and community strength, stores-as-hubs, same-day fulfillment, retail media and owned-brand renewal.

A closer look at the financial trajectory of F. Hoffmann-La Roche AG and Target Corporation rounds out the comparison.

F. Hoffmann-La Roche AG: Roche reported CHF 61.5 billion in 2025 group sales. Pharmaceuticals sales were CHF 47.7 billion and Diagnostics sales were CHF 13.8 billion. Core operating profit was CHF 21.8 billion, and R&D core investments were CHF 12.2 billion. For USD comparability, this profile converts CHF 61.5 billion at 1 CHF = 1.25506 USD.

Target Corporation: Target reported FY2025 revenue of $104.780B and net income of $3.705B. Q1 FY2026 net sales increased 6.7%, with comparable sales up 5.6% and EPS of $1.71.